New combo therapy aims to keep rare urinary tract cancer at bay
NCT ID NCT07225374
First seen Nov 06, 2025 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This study tests whether giving a maintenance immunotherapy drug (avelumab) after standard chemotherapy can help prevent upper tract urothelial cancer from coming back. About 48 adults who have already completed chemo and show no signs of cancer will receive avelumab every two weeks for up to two years. The goal is to see if this approach extends the time patients remain cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, Gangnam, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.